◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Wanbury Limited (WANBURY) Financial History

Name: Wanbury Limited (WANBURY) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Wanbury Limited (WANBURY) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Navi Mumbai, India with about 1,200 employees. Its market capitalization is roughly ₹8 billion. In the fiscal year ended 2026-03-31, WANBURY reported ₹6.4B in revenue and ₹661M in net income.

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally.

Interactive charts & full statements →

WANBURY Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹6.4B	₹5.9B	₹5.7B	₹5.0B
Gross Profit	₹3.6B	₹2.9B	₹2.6B	₹1.9B
Operating Income (EBIT)	₹2.7B	₹702M	₹572M	₹119M
Net Income	₹661M	₹305M	₹560M	(₹104M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WANBURY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹1.7B	₹1.6B	₹1.6B	₹1.6B	₹1.6B	—
Gross Profit	₹866M	₹993M	₹936M	₹930M	₹878M	—
Operating Income (EBIT)	₹122M	₹266M	₹230M	₹221M	₹208M	—
Net Income	₹32M	₹217M	₹158M	₹152M	₹135M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WANBURY Free Cash Flow History

WANBURY Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹5.2B	₹4.1B	₹3.4B	₹3.0B	—
Total Liabilities	₹3.7B	₹3.5B	₹3.2B	₹3.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive WANBURY viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

ANUHPHR · Anuh Pharma Limited — ₹9 billion
4524 · Morishita Jintan Co., Ltd. — JPY 9 billion
SGRL · Shree Ganesh Remedies Limited — ₹9 billion
2005 · SSY Group Limited — HK$8 billion
APTX · Apotex Health Corp. — C$8 billion
BAFNAPH · Bafna Pharmaceuticals Limited — ₹8 billion
AMANTA · Amanta Healthcare Limited — ₹7 billion
ZIMLAB · ZIM Laboratories Limited — ₹7 billion

← WAMA All “W” companies WANT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.